TESARO (TSRO) has risen sharply, recording gains of 18.11% in the past 4 weeks. However, the stock has corrected -7.69% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 18.75% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 1.71% and the 50-Day Moving Average is 5.8%.The 200 Day SMA reached 70.01%
TESARO (NASDAQ:TSRO): The stock opened in the green at $101.34 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $101.34 and a low of $96.56 for the day. The stock did not find buyers even at the lows and closed at $100.24 recording a loss of -0.34%. 1,293,548 shares exchanged hands during the trading day. The stock had closed at $100.24 in the previous days trading.
TESARO (TSRO) : The highest level TESARO (TSRO) is projected to reach is $130 for the short term and the lowest estimate is at $80. The consolidated price target from 10 rating analysts who initiate coverage on the stock is $104.8 and the possibility the share price can swing is $12.66.
TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., for the discovery and development of antibodies for several specified immuno-oncology targets.